Inhibition of Experimental Corneal Neovascularization by 实验性角膜新生血管的抑制作用.pptVIP

Inhibition of Experimental Corneal Neovascularization by Bevacizumab (Avastin) Baskent University, School of Medicine Department of Ophthalmology, Ankara Turkey Purpose To evaluate and compare the inhibitory effects of topical high dose, low-dose and subconjunctival bevacizumab (Avastin, Genentech Inc., San Francisco, Ca, USA) on corneal vascularization in a rat model Methods Corneas of 20 rats (Sprague-Dawley, male) were chemically cauterized with silver nitrate sticks in order to induce neovascularization Animals were divided in four groups Methods Digital photographs of the corneas were taken and analyzed using an image analysis software (Pixcavator Image Analyzer, Intelligent Perception,WV, USA) On day 10, all animals were sacrificed and the eyes were enucleated Corneas were excised and examined histopathologically Results In histological examination of the excised corneas, treated eyes showed significantly less neovascular areas and number of vessels in group 2,3 and 4 than the control group The differences between control group and treatment groups were found to be statistically significant (p 0.05 for all) Bevacizumab is able to inhibit corneal angiogenesis, without any difference of this effect with Changing the route of administration (subconjunctival or topical) Increasing the dosage (4mg/ml or 12.5mg/ml for topical form) Discussion Both topical and subconjunctival application of bevacizumab reduces experimental corneal vascularization significantly compared to the control group Clinical use of bevacizumab may have an additional effect in the treatment for corneal neovascularization * Yonca A. Akova, MD Veysi ?ner, MD Cem Kü?ükerd?nmez, MD The authors acknowledge no financial interest in the subject matter of this presentation Group 1: Control group that received only topical artificial tear twice daily Grup 2: Subconjunctival injection group that received 0.05 ml (1.25mg) of bevacizumab on day 1, 4 and 7 Group 3: Lo